Similar articles

• Prostate-specific antigen and screening for prostate cancer.

  Han M, Gann PH, Catalona WJ. Han M, et al. Med Clin North Am. 2004 Mar;88(2):245-65, ix. doi: 10.1016/S0025-7125(03)00188-3. Med Clin North Am. 2004. PMID: 15049577 Review.
• What can be concluded from the ERSPC and PLCO trial data?

  Studer UE, Collette L. Studer UE, et al. Urol Oncol. 2010 Nov-Dec;28(6):668-9. doi: 10.1016/j.urolonc.2010.03.011. Urol Oncol. 2010. PMID: 21062648
• Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.

  Agalliu I, Weiss NS, Lin DW, Stanford JL. Agalliu I, et al. Cancer Causes Control. 2007 Nov;18(9):931-7. doi: 10.1007/s10552-007-9031-7. Epub 2007 Jul 20. Cancer Causes Control. 2007. PMID: 17641982
• The effectiveness of screening for prostate cancer: a nested case-control study.

  Concato J, Wells CK, Horwitz RI, Penson D, Fincke G, Berlowitz DR, Froehlich G, Blake D, Vickers MA, Gehr GA, Raheb NH, Sullivan G, Peduzzi P. Concato J, et al. Arch Intern Med. 2006 Jan 9;166(1):38-43. doi: 10.1001/archinte.166.1.38. Arch Intern Med. 2006. PMID: 16401808
• PSA screening.

  Cohen S, Schiff S, Kelty P. Cohen S, et al. Med Health R I. 2005 Mar;88(3):90-1. Med Health R I. 2005. PMID: 15915782 Review. No abstract available.